Pharmgate LLC of Ramsey, NJ, announces the approval of its flagship product, Deracin® 22% Granular Premix containing 22% chlortetracycline, by the Veterinary Drugs Directorate of Health Canada. As the majority-owned U.S. subsidiary of Jinhe Biotechnology, the largest manufacturer of chlortetracycline in the world, Pharmgate will become a significant supplier of branded chlortetracycline products in Canada.
This generic approval carries all important label claims for the drug across livestock and poultry species. Deracin 22% Granular Premix is a high-quality, free-flowing, and dust-free granule that is manufactured and formulated in the plant that has enjoyed a 20 year history of supplying FDA-compliant products.
The product is supplied in 25kg bags and will be made available to feedmills and livestock producers in the coming months. It will be marketed by Pharmgate Animal Health, Pharmgate’s marketing joint venture in North America, alongside its first product offering, Aivlosin® (tylvalosin) Water Soluble Granules, which has received considerable support from the livestock community since its launch last year.
Colin Gray, CEO of Pharmgate commented, “This is another important step in the evolution of Jinhe/Pharmgate from the largest global supplier of high quality CTC to a fully integrated and recognized animal health company. We, in company with our partners and in utilizing Pharmgate’s significant supply chain, regulatory and marketing expertise look forward to building on this success in adding future complementary products over the next several years.”